论文部分内容阅读
目的探讨依达拉奉联合低分子肝素治疗急性进展性脑梗死的疗效及其安全性。方法将80例急性进展性脑梗死病例随机分为治疗组(40例)和对照组(40例),两组基础治疗相同,治疗组采用依达拉奉30mg加入生理盐水100ml,静脉滴注,2次/d,共14d,低分子肝素钠5000IU,脐周皮下注射,1次/12h,共7d;对照组应用常规综合治疗。观察比较两组的临床疗效及神经功能缺损程度评分。结果治疗组显效率、总有效率分别为62.5%、80%,对照组分别为32.5%、57.5%,两组显效率、总有效率均差异有统计学意义(P<0.05);神经功能缺损程度评分治疗组显著低于对照组(P<0.05)。两组均无明显不良反应。结论依达拉奉联合低分子肝素治疗进展性脑梗死疗效明显优于常规综合治疗。
Objective To investigate the efficacy and safety of edaravone combined with low molecular weight heparin in the treatment of acute progressive cerebral infarction. Methods Eighty patients with acute progressive cerebral infarction were randomly divided into treatment group (40 cases) and control group (40 cases). The two groups had the same basic treatment. The patients in treatment group were given edaravone 30mg, 2 times / d, a total of 14d, low molecular weight heparin 5000IU, umbilical subcutaneous injection, 1 / 12h, a total of 7d; control group using conventional comprehensive treatment. The clinical efficacy and the score of neurological deficit in the two groups were observed and compared. Results The effective rate and total effective rate were 62.5% and 80% respectively in the treatment group and 32.5% and 57.5% in the control group respectively. There was significant difference between the two groups in the effective rate and the total effective rate (P <0.05) Degree scoring treatment group was significantly lower than the control group (P <0.05). No significant adverse reactions in both groups. Conclusion Edaravone combined with low molecular weight heparin treatment of progressive cerebral infarction was significantly better than the conventional comprehensive treatment.